Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
ATP-Binding Cassette Transporters / genetics
-
ATP-Binding Cassette Transporters / physiology
-
Adaptation, Physiological
-
Antineoplastic Agents / pharmacokinetics*
-
Apoptosis / physiology
-
Apoptosis Regulatory Proteins / physiology
-
Autophagy
-
Biological Transport
-
Biotransformation
-
DNA Damage
-
DNA Repair
-
Drug Design
-
Drug Resistance, Neoplasm* / genetics
-
Drug Resistance, Neoplasm* / physiology
-
Epithelial-Mesenchymal Transition
-
Gene Expression Regulation, Neoplastic
-
Gene Silencing
-
Humans
-
Models, Biological
-
Molecular Targeted Therapy
-
Mutation
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / physiology
-
Neoplastic Stem Cells / drug effects
-
Neoplastic Stem Cells / metabolism
-
Neoplastic Stem Cells / pathology
-
Tumor Microenvironment
Substances
-
ATP-Binding Cassette Transporters
-
Antineoplastic Agents
-
Apoptosis Regulatory Proteins
-
Neoplasm Proteins